Wentworth Jarrett, MD
Family Medicine · Miami, FLNPI 1104836972
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,272 of the $11,461 with a category attached, or 89.6%. It is spread thinly across 38 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Merck$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$692
- Pfizer$580
- plus $5K from 32 others
Across 92 payments — averaging $11,561 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$883K
- GSK$49K
- Pfizer$47K
- Astellas Pharma Global Development$47K
- AstraZeneca$20K
- Novartis$13K
- plus $6K from 1 others
What the payments were for
- Travel & lodging$9718%
- Food & beverage$10,27290%
- Education$2182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $1,657 |
| AstraZeneca | 58 | $1,552 |
| Merck | 20 | $1,395 |
| Lilly USA, LLC | 70 | $1,033 |
| Boehringer Ingelheim | 21 | $692 |
| Pfizer | 26 | $580 |
| Sanofi-aventis U.S. LLC | 26 | $481 |
| GSK | 22 | $478 |
| Johnson & Johnson | 22 | $477 |
| Astellas Pharma US Inc | 8 | $376 |
| Amgen(2 entities) | 17 | $348 |
| Exact Sciences | 10 | $235 |
| Edwards Lifesciences | 3 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $209 |
| Abbott | 12 | $205 |
| Corcept Therapeutics | 7 | $199 |
| Radius Health, Inc. | 4 | $189 |
| Bayer | 9 | $185 |
| Novartis | 5 | $179 |
| Boston Scientific | 1 | $141 |
| Amarin Pharma, Inc. | 6 | $102 |
| Inspire Medical Systems, Inc. | 1 | $80 |
| E.r. Squibb & Sons, L.L.C. | 3 | $72 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
| AbbVie | 3 | $48 |
| Dexcom, Inc. | 2 | $41 |
| Eisai Inc. | 1 | $34 |
| VBI Vaccine (delaware) Inc. | 1 | $27 |
| Galderma Laboratories, L.p. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $21 |
| Lifescan, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,461 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 82 | $113,324 |
| OzempicSemaglutide | 103 | $107,631 |
| JardianceEmpagliflozin | 82 | $104,592 |
| FarxigaDapagliflozin Propanediol | 52 | $66,789 |
| TradjentaLinagliptin | 48 | $54,172 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $36,216 |
| ProliaDenosumab | 18 | $31,321 |
| JanuviaSitagliptin Phosphate | 29 | $29,295 |
| MounjaroTirzepatide | 20 | $22,532 |
| TrulicityDulaglutide | 12 | $22,493 |
| XareltoRivaroxaban | 15 | $18,911 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $18,259 |
| TrintellixVortioxetine Hydrobromide | 17 | $17,778 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $17,661 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $16,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $692 | $171,797142 claims |
| PfizerEliquis, Paxlovid | $580 | $116,12193 claims |
| Novo NordiskOzempic | $1,657 | $107,631103 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,552 | $88,77792 claims |
| MerckJanuvia, Janumet, Janumet Xr | $1,395 | $63,10462 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,033 | $45,02532 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $481 | $36,21636 claims |
| AmgenProlia | $348 | $31,32118 claims |
| Johnson & JohnsonXarelto | $477 | $18,91115 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $209 | $17,77817 claims |
| AbbVieLinzess | $48 | $14,40517 claims |
| Astellas Pharma US IncMyrbetriq | $376 | $9,77618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.